MA51586A - Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci - Google Patents

Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci

Info

Publication number
MA51586A
MA51586A MA051586A MA51586A MA51586A MA 51586 A MA51586 A MA 51586A MA 051586 A MA051586 A MA 051586A MA 51586 A MA51586 A MA 51586A MA 51586 A MA51586 A MA 51586A
Authority
MA
Morocco
Prior art keywords
immunoconjugate
agonist
glucocorticoid receptor
glucocorticoid
receptor
Prior art date
Application number
MA051586A
Other languages
English (en)
Inventor
Christian Goess
Martin E Hayes
Jr Axel Hernandez
Adrian D Hobson
Christopher C Marvin
Michael J Mcpherson
Jason Z Oh
John T Randolph
Diana Schmidt
Wendy Waegell
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59215995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51586(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA51586A publication Critical patent/MA51586A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA051586A 2016-06-02 2017-06-01 Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci MA51586A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344948P 2016-06-02 2016-06-02
US201662371134P 2016-08-04 2016-08-04

Publications (1)

Publication Number Publication Date
MA51586A true MA51586A (fr) 2019-04-10

Family

ID=59215995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051586A MA51586A (fr) 2016-06-02 2017-06-01 Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci

Country Status (36)

Country Link
US (4) US20180126000A1 (fr)
EP (2) EP3901162A1 (fr)
JP (2) JP6843891B2 (fr)
KR (2) KR20220119529A (fr)
CN (1) CN109476699B (fr)
AU (2) AU2017274442B2 (fr)
BR (1) BR112018074922B1 (fr)
CA (1) CA3025377A1 (fr)
CL (1) CL2018003406A1 (fr)
CO (1) CO2018012996A2 (fr)
CR (1) CR20180594A (fr)
CY (1) CY1124293T1 (fr)
DK (1) DK3464318T3 (fr)
DO (1) DOP2018000261A (fr)
EC (1) ECSP18094857A (fr)
ES (1) ES2877548T3 (fr)
HR (1) HRP20210924T1 (fr)
HU (1) HUE054804T2 (fr)
IL (1) IL263214B2 (fr)
LT (1) LT3464318T (fr)
MA (1) MA51586A (fr)
MX (2) MX382216B (fr)
MY (1) MY194619A (fr)
PE (1) PE20190622A1 (fr)
PH (1) PH12018502539A1 (fr)
PL (1) PL3464318T3 (fr)
PT (1) PT3464318T (fr)
RS (1) RS62040B1 (fr)
RU (1) RU2745748C2 (fr)
SG (2) SG11201810678WA (fr)
SI (1) SI3464318T1 (fr)
TW (1) TWI728118B (fr)
UA (1) UA124703C2 (fr)
UY (1) UY37269A (fr)
WO (1) WO2017210471A1 (fr)
ZA (1) ZA201808623B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62040B1 (sr) * 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
CA3042428A1 (fr) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroides et leurs conjugues proteiques
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EP3658192B1 (fr) * 2017-12-01 2021-04-28 AbbVie Inc. Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
RU2020117156A (ru) * 2017-12-01 2022-01-04 Эббви Инк. Конъюгаты анти-cd40 антитела и лекарственного средства
MA50259A1 (fr) * 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2019217591A1 (fr) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procédés d'utilisation
JP2022517767A (ja) * 2019-01-08 2022-03-10 レゲネロン ファーマシューティカルス，インコーポレーテッド 無痕跡型リンカー及びそのタンパク質－コンジュゲート
WO2020206149A2 (fr) * 2019-04-05 2020-10-08 The Regents Of The University Of California Méthodes et compositions impliquant des polypeptides de liaison chimères
WO2021161263A1 (fr) * 2020-02-13 2021-08-19 Abbvie Inc. Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
CN116096413A (zh) * 2020-04-22 2023-05-09 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
MX2023005093A (es) * 2020-11-03 2023-05-18 Ads Therapeutics Llc Conjugados oculares de anticuerpo-farmaco.
WO2022135332A1 (fr) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 Conjugué de stéroïdes
EP4271387A4 (fr) * 2021-01-07 2026-01-28 Immunext Inc Nouvelle charge utile de stéroïde, lieurs de stéroïdes, cam les contenant et utilisation associée
TWI924779B (zh) * 2021-02-04 2026-05-11 大陸商上海森輝醫藥有限公司 糖皮質激素受體激動劑的藥物偶聯物及其在醫藥上的應用
WO2022171101A1 (fr) * 2021-02-10 2022-08-18 映恩生物制药（苏州）有限公司 Conjugué de stéroïdes
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
EP4365183A4 (fr) * 2021-06-24 2025-12-03 Jiangsu Simcere Pharm Co Ltd Composé stéroïde, composition pharmaceutique et utilisation associées
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
JP2024531480A (ja) * 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
US20250179114A1 (en) * 2021-09-14 2025-06-05 Duality Biologics (Suzhou) Co., Ltd. Anti-Inflammatory Compound and Use Thereof
US20250154242A1 (en) 2021-11-18 2025-05-15 Adafre Biosciences, Llc Anti-tnf-alpha antibodies and compositions
EP4470569A1 (fr) 2022-01-29 2024-12-04 Shanghai Shengdi Pharmaceutical Co., Ltd Conjugué de médicament de glucocorticoïde
WO2023186072A1 (fr) * 2022-04-01 2023-10-05 江苏先声药业有限公司 Conjugué ligand-médicament et son utilisation
CN119744180A (zh) 2022-05-13 2025-04-01 伊莱利利公司 人肿瘤坏死因子α抗体糖皮质激素缀合物
WO2023235738A1 (fr) 2022-06-02 2023-12-07 Eli Lilly And Company Conjugués glucocorticoïdes d'anticorps alpha du récepteur de l'interleukine-4 humaine
WO2023245106A1 (fr) 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Conjugués médicament-anticorps anti-cd19
AU2023289376A1 (en) 2022-06-22 2025-01-16 Eli Lilly And Company Human cd33 antibodies and glucocorticoid conjugates
US20250388665A1 (en) 2022-06-28 2025-12-25 Adafre Biosciences, Llc Anti-tnf-alpha antibodies and compositions
WO2024020164A2 (fr) 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués
JP2025532110A (ja) * 2022-09-22 2025-09-29 イーライ リリー アンド カンパニー グルココルチコイド受容体アゴニスト
CN118236514B (zh) * 2022-12-24 2025-10-31 津药生物科技（天津）有限公司 抗体-糖皮质激素偶联物及其用途
WO2024140917A1 (fr) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 Conjugué anticorps-médicament anti-cd40, son procédé de préparation et son utilisation médicale
WO2024140838A1 (fr) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 Conjugué anticorps-médicament anti-bdca2 et son utilisation
TW202444433A (zh) * 2023-04-26 2024-11-16 大陸商上海邁晉生物醫藥科技有限公司 一種含有糖皮質激素受體激動劑的藥物偶聯物的醫藥組成物
TW202506196A (zh) 2023-07-28 2025-02-16 大陸商江蘇恒瑞醫藥股份有限公司 含有糖皮質激素的抗體藥物偶聯物的藥物組合物
IL327670A (en) 2023-10-11 2026-06-01 Antikor Biopharma Ltd Antibodies, conjugates, and uses thereof
WO2026051856A1 (fr) * 2024-09-06 2026-03-12 四川科伦博泰生物医药股份有限公司 Agoniste du récepteur des glucocorticoïdes et conjugué associé

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
GB933867A (en) 1958-12-08 1963-08-14 American Cyanamid Co Fluorinated steroids
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5010176A (en) 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (fr) 1991-12-13 1993-06-24 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CZ287877B6 (cs) 1993-04-02 2001-03-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Prednisolonové deriváty a farmaceutické prostředky s jejich obsahem
WO1994025478A1 (fr) 1993-04-29 1994-11-10 Instytut Farmaceutyczny DERIVES GLUCOCORTICOSTEROIDAUX DE 16α,17α-ACETAL
WO1995024416A1 (fr) 1994-03-09 1995-09-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux composes silyle et leur utilisation
JP2749778B2 (ja) 1994-09-05 1998-05-13 日清食品株式会社 トリアムシノロン誘導体
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0859841B1 (fr) 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE10055820C1 (de) 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
DE60142920D1 (de) 2000-11-10 2010-10-07 Nycomed Gmbh Verfahren zur herstellung von 16,17-ä(cyclohexylmethylen)bis(oxy)ü -11,21-dihydroxy-pregna-1,4-dien-3,20-dion oder ihre 21-isobutyrat durch transketalisation
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP2292273A3 (fr) 2001-10-10 2011-11-23 BioGeneriX AG Remodelage et Glycoconjugaison de Peptides
AU2002351957B2 (en) 2001-11-12 2009-09-03 Merck Patent Gmbh Modified anti-TNF alpha antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1562627A4 (fr) 2002-08-23 2006-11-02 Mclean Hospital Corp Conjugues de corticosteroides et utilisations de ceux-ci
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1567113A4 (fr) 2002-10-24 2006-11-08 G & R Pharmaceuticals Llc Preparations antifongiques
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
AU2003296984A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
WO2005044759A2 (fr) 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalisation pour preparation de composes steroides
WO2005025578A1 (fr) 2003-09-16 2005-03-24 Altana Pharma Ag Utilisation de ciclesonide dans le traitement de maladies respiratoires
WO2005028495A1 (fr) 2003-09-24 2005-03-31 Glaxo Group Limited Glucocorticoïdes anti-inflammatoires
EP1680073B1 (fr) 2003-10-21 2013-01-02 IGF Oncology, LLC Composes et methode de traitement du cancer
WO2005047284A1 (fr) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Pyrido-7-pyrimidin-7-ones substitues hydroxyalkyle
HRP20070241T3 (hr) 2003-12-19 2007-07-31 Bristol-Myers Squibb Company Azabiciklički heterocikli kao modulatori kanabinoid receptora
WO2005063777A1 (fr) 2003-12-23 2005-07-14 Corus Pharma Promedicaments de benzylphosphate et de benzylphosphate substitue utilises dans le traitement d'une inflammation pulmonaire
WO2005065435A2 (fr) 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Formulation de substance a inhaler contenant du sulfoalkyle ether cyclodextrine et un corticosteroide
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1725585A2 (fr) 2004-03-10 2006-11-29 Lonza Ltd Procede de production d'anticorps
EP3342782B1 (fr) 2004-07-15 2022-08-17 Xencor, Inc. Variantes optimisées de fc
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
CA2579007A1 (fr) 2004-09-10 2006-03-16 Altana Pharma Ag Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
WO2006097458A1 (fr) 2005-03-15 2006-09-21 Nycomed Gmbh Nouvelle combinaison
WO2006110593A2 (fr) 2005-04-07 2006-10-19 Macrogenics, Inc. Cibles biologiques pour le diagnostic, le traitement et la prevention du cancer
EP1712220A1 (fr) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Composition d'aérosol pharmaceutique
WO2006135479A2 (fr) 2005-05-10 2006-12-21 Angiotech International Ag Agents anti-cicatrisation, compositions therapeutiques, et leurs utilisations
AU2006259604A1 (en) 2005-06-14 2006-12-28 Gilead Sciences, Inc. Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction
AU2006262231B2 (en) 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
WO2007054974A2 (fr) 2005-09-28 2007-05-18 Arch Pharmalab Limited Procede de chimie verte pour la preparation d’esters de pregnadiene
EP2004231A4 (fr) 2006-04-07 2013-07-10 Nektar Therapeutics Conjugues d'un anticorps anti-tnf-alpha
WO2008015696A2 (fr) 2006-05-23 2008-02-07 Cadila Healthcare Limited Procédé pour préparer le ciclésonide
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
EP2064227A2 (fr) 2006-09-19 2009-06-03 Cipla Ltd. Méthodes de préparation de ciclésonide et sa modification cristalline
WO2008052350A1 (fr) 2006-11-03 2008-05-08 Qlt Inc. Thérapie photodynamique pour le traitement de l'hidradenitis suppurativa
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
NO331891B1 (no) 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
JP2010531898A (ja) 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
EP2225256B1 (fr) 2007-11-30 2013-01-09 Pfizer Limited Nouveaux agonistes des récepteurs des glucocorticoïdes
US20110262368A1 (en) 2007-12-21 2011-10-27 Schering Corporation C21 thioethers as glucocorticoid receptor agonists
CN101970452A (zh) 2007-12-21 2011-02-09 先灵公司 C20-c21取代的糖皮质激素受体激动剂
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
BRPI0907789A2 (pt) 2008-02-27 2019-01-22 Astrazeneca Ab derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP2011513469A (ja) 2008-03-13 2011-04-28 ファルマビオス ソシエタ ペル アチオニ プレグナン誘導体の製造法
EP2294077A1 (fr) 2008-06-10 2011-03-16 Gilead Sciences, Inc. Composés bêta agonistes liés à des corticostéroïdes en vue d'une utilisation en thérapie
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
WO2010008831A2 (fr) 2008-06-24 2010-01-21 Irm Llc Composés et procédés pour moduler les récepteurs couplés à la protéine g
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
ES2471145T3 (es) 2009-03-09 2014-06-25 Mikasa Seiyaku Co,. Ltd. Compuesto esteroide
WO2010126953A1 (fr) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Composés bêta-agonistes liés à des corticostéroïdes pour une utilisation en thérapie
WO2010132743A1 (fr) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Composés de β-agonistes et de corticostéroïdes destinés à être utilisés en thérapie
EP2435462A1 (fr) 2009-05-29 2012-04-04 Pfizer Limited Nouveaux agonistes du récepteur des glucocorticoïdes
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
CA2781682A1 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispecifiques, analogues d'anticorps, compositions et procedes
CN102665757A (zh) 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
WO2011133886A2 (fr) 2010-04-23 2011-10-27 Genentech, Inc. Production de protéines hétéromultimères
CA2927832C (fr) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Conjugues d'agent therapeutique polymere renfermant de la cyclodextrine et leur utilisation
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
BR112012032778A2 (pt) 2010-06-24 2019-09-24 Abbvie Inc "proteínas multiespecíficas e multivalentes"
AU2011305566A1 (en) 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2012082947A1 (fr) 2010-12-16 2012-06-21 Irm Llc Composés et compositions en tant qu'agonistes de tgr5
WO2012089247A1 (fr) 2010-12-29 2012-07-05 Nokia Siemens Networks Oy Procédé et appareil permettant de transmettre une identité
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
JP5827511B2 (ja) 2011-07-25 2015-12-02 新日鉄住金エンジニアリング株式会社 石炭ガスの製造方法およびメタンの製造方法
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
US20130115269A1 (en) 2011-11-04 2013-05-09 Henry John Smith Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases
WO2013087914A1 (fr) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Expression d'anticorps iga sécrétoires chez la lentille d'eau
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
CN103421075B (zh) 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
EP2855745A4 (fr) 2012-06-01 2016-01-20 Momenta Pharmaceuticals Inc Méthodes associées à l'adalimumab
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2015012904A2 (fr) 2012-12-13 2015-01-29 Immunomedics, Inc. Immunoconjugués anticorps-sn-38 avec un lieur cl2a
ES2706757T3 (es) 2012-12-21 2019-04-01 Boehringer Ingelheim Vetmedica Gmbh Formulación farmacéutica que comprende ciclesonida
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
US20140294813A1 (en) 2013-03-15 2014-10-02 Abbvie, Inc. TNF Binding Proteins
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
BR112015024386A2 (pt) * 2013-03-27 2017-07-18 Koninklijke Philips Nv soquete para conectar eletricamente uma lâmina de oled, lâmina de oled, painel de lâmina de oled, e, fonte de luz
CA2920192A1 (fr) 2013-09-27 2015-04-02 Immunomedics, Inc. Conjugues anticorps anti-trop-2-medicament et leurs utilisations
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
EP3125943B1 (fr) * 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Lieurs à base de phosphates pour introduction intracellulaire de conjugués médicamenteux
EP3160499A4 (fr) 2014-06-30 2018-03-14 Immunomedics, Inc. Anticorps réagissant avec un épitope situé dans la région n-terminale de muc5ac comprenant un sous-domaine 2 riche en cystéine (cys2)
CN107405306A (zh) 2014-09-19 2017-11-28 奥叙拉尔有限公司 眼部药物组合物
EP3250211B1 (fr) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Nouveau procédé de préparation de stéroïdes de type glucocorticoïde
JP2016190798A (ja) 2015-03-31 2016-11-10 三笠製薬株式会社 アレルギー性鼻炎治療用局所点鼻薬
JP2017066075A (ja) 2015-09-30 2017-04-06 三笠製薬株式会社 リウマチ治療薬
RS62040B1 (sr) * 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
CA3042428A1 (fr) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroides et leurs conjugues proteiques

Also Published As

Publication number Publication date
MX2018014927A (es) 2019-04-09
JP2021088582A (ja) 2021-06-10
US10668167B2 (en) 2020-06-02
PE20190622A1 (es) 2019-04-26
ZA201808623B (en) 2019-08-28
ES2877548T3 (es) 2021-11-17
AU2021269433A1 (en) 2021-12-16
EP3464318B1 (fr) 2021-04-21
PL3464318T3 (pl) 2021-11-08
UY37269A (es) 2018-01-02
RS62040B1 (sr) 2021-07-30
TW201801749A (zh) 2018-01-16
SI3464318T1 (sl) 2021-07-30
SG11201810678WA (en) 2018-12-28
JP2019524645A (ja) 2019-09-05
TWI728118B (zh) 2021-05-21
EP3464318A1 (fr) 2019-04-10
US20200338208A1 (en) 2020-10-29
JP6843891B2 (ja) 2021-03-17
HRP20210924T1 (hr) 2021-09-03
CY1124293T1 (el) 2022-07-22
IL263214B2 (en) 2023-06-01
CA3025377A1 (fr) 2017-12-07
MX2020012562A (es) 2021-02-09
RU2018145728A3 (fr) 2020-08-04
US20180126000A1 (en) 2018-05-10
UA124703C2 (uk) 2021-11-03
RU2018145728A (ru) 2020-07-10
ECSP18094857A (es) 2019-01-31
IL263214A (en) 2018-12-31
MX382216B (es) 2025-03-13
LT3464318T (lt) 2021-06-25
SG10202001787QA (en) 2020-04-29
BR112018074922B1 (pt) 2022-10-25
AU2017274442A1 (en) 2018-12-13
CL2018003406A1 (es) 2019-02-15
WO2017210471A1 (fr) 2017-12-07
EP3901162A1 (fr) 2021-10-27
PH12018502539A1 (en) 2019-09-30
CN109476699A (zh) 2019-03-15
HUE054804T2 (hu) 2021-09-28
KR20190014542A (ko) 2019-02-12
DOP2018000261A (es) 2018-12-31
DK3464318T3 (da) 2021-06-28
CN109476699B (zh) 2021-10-12
MY194619A (en) 2022-12-07
BR112018074922A2 (pt) 2019-03-12
CR20180594A (es) 2019-07-29
US20220354959A1 (en) 2022-11-10
PT3464318T (pt) 2021-07-02
KR102435599B1 (ko) 2022-08-29
US20190262465A1 (en) 2019-08-29
CO2018012996A2 (es) 2019-01-18
AU2017274442B2 (en) 2021-08-19
KR20220119529A (ko) 2022-08-29
RU2745748C2 (ru) 2021-03-31

Similar Documents

Publication Publication Date Title
MA49796A (fr) Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
ZA201808623B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
EP3609888A4 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3596053A4 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3605504A4 (fr) Dispositif de détermination, procédé de détermination, et programme
EP3852737A4 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3472208C0 (fr) Récepteurs de lymphocytes t et leurs utilisations
EP3532100A4 (fr) Anticorps anti-pd-l1 et variants
EP3693391C0 (fr) Anticorps et immunoconjugués anti-cll-1
EP3440870A4 (fr) Dispositifs et procédés pour v2x mec
EP3719796A4 (fr) Dispositif de synthèse vocae, procédé de synthèse vocale et programme
EP3523315A4 (fr) Inhibiteurs de récepteurs glucocorticoïdes
EP3674694A4 (fr) Procédé et dispositif d'analyse
EP3547121A4 (fr) Dispositif, procédé et programme de combinaison
EP3598111A4 (fr) Dispositif d'inspection et procédé d'inspection
DK3555633T3 (da) Prøve-modtageanordning og -sonde
EP3623062A4 (fr) Dispositif de nettoyage et appareil de nettoyage
EP3505963A4 (fr) Dispositif de mesure, procédé de mesure et programme
EP3598374A4 (fr) Dispositif de relais et programme
EP3611941A4 (fr) Dispositif d'émission vocale, procédé d'émission vocale, et programme
EP3637092A4 (fr) Dispositif d'inspection et procédé d'inspection
EP3557249A4 (fr) Dispositif de test d'urine et procédé de test d'urine
EP3744738A4 (fr) Récepteur antigénique chimérique et application associée
EP3582120A4 (fr) Dispositif et procédé de traduction
EP3805879A4 (fr) Dispositif d'assistance et programme d'assistance